Business · 25/10/20261 min read
Positive overall survival results from the Phase III HARMONi-GI1 trial of Ivonescimab Plus Chemotherapy versus Durvalumab Plus Chemtherapy in first-line biliary tract cancer Presented at the ESMO 2026 Presidential Symposium
Summary
HONG KONG, Oct. 25, 2026 — Akeso, Inc. (HKEX: 9926. HK) today announced the presentation of results from the randomized, controlled, double-blind, multicenter, registration phase III HARMONi-GI1 trial (...